Market Research Logo

Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016


Attention: There is an updated edition available for this report.

What Will the Pharma Industry Look Like in 5 Years?

There are an estimated 724 projects in development from the top 50 pharmaceutical companies.  Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors?   In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies that produce the lion's share of industry revenues.

Coverage of the 50 Leading Companies

 This report takes a look at the pipeline of the following companies.  The top companies include pharmaceutical companies that are considered to be the top 50 companies worldwide in terms of generated revenues, these include:

  • Abbott Laboratories
  • Actelion
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen IDEC
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • CSL
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly & Co.
  • Forest
  • Gilead Sciences
  • GlaxoSmithKline
  • Grifols SA
  • Hospira
  • Johnson & Johnson
  • Kyowa Kirin
  • Lundbeck
  • Menarini
  • Merck
  • Merck KGaA
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Novartis
  • Novo Nordisk
  • Ono Pharmaceutical Co.
  • Otsuka Pharmaceutical
  • Pfizer
  • Purdue Pharma
  • Reckitt Benckiser
  • Roche
  • Sanofi
  • Santen Pharmaceuticals
  • Servier
  • Shionogi
  • Shire
  • Taisho Pharmacueitcal
  • Takeda
  • TEVA
  • UCB
  • Valeant Pharmaceuticals
  • Warner Chilcott
  • Watson

While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products.  The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

Pipeline Analysis, Key Trends, Market Forecasts

This Kalorama Information market research report captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines and OTC products) and providing estimates and forecasts of the world biopharma market.

As part of its coverage, the report provides the following:
  • Company Analysis
  • Pipeline Snapshot: Top 20 Companies
  • Market Trends and Value
  • Evaluating Changes in 2011 Market Value
  • The Traditional Pharmaceutical Market
  • Biotechnology Market Facts and Forecast

For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals and products; diagnostics; devices; chemicals; agriculture; and animal health. These are areas where many of these companies also compete with significant market shares.

The industry has struggled in recent years but many observers see biopharmaceutical as the key to continued success for market leaders.  Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses. The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization. 

Issues and Trends discussed in this report include:

  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • Biosimilar Development
  • Aging Populations
  • Mergers, Acquisitions, and Collaborations
  • Contributors to R&D Success
  • R&D Spending Trends
  • The Role of Contract Research Organizations
  • Sustainability in a Changing Pharmaceutical Industry


  • Executive Summary
    • INTRODUCTION
    • SCOPE AND METHODOLOGY
    • POTENTIAL MARKET OPPORTUNITY
      • Table Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016-based on late stage development projects evaluated ($ in billions)
    • ISSUES AND TRENDS AFFECTING MARKET
    • LEADING COMPANIES
  • Introduction
    • GLOBAL PHARMACEUTICAL MARKET
      • Table Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000 and 2009
    • PHARMACEUTICAL RESEARCH&DEVELOPMENT OVERVIEW
      • Table Phases of Clinical Drug Development
      • Table Components of a Clinical Trial
    • EXPANDED OPTIONS IN TREATING DISEASES
  • Issues and Trends
    • BIOTECHNOLOGY DRUG DEVELOPMENT
    • ORPHAN DRUGS
    • FAST TRACK DRUG STATUS
    • OTHER ACCELERATED METHODS FOR DRUG APPROVAL
    • PHARMACEUTICAL REGULATORY EXCLUSIVITY
      • Pediatric Extensions
    • BIOPHARMACEUTICAL INDUSTRY-BIOSIMILAR (BIOGENERIC) DEVELOPMENT AND EXCLUSIVITY LEGISLATION
    • AGING POPULATION
      • Table International Population Trend Age 65+ (Thousands)
      • Table United States Population Trend Age 65+ (Thousands)
    • MERGERS,ACQUISITIONS, AND COLLABORATIONS
      • Table Recent Pharmaceutical Business Mergers and Acquisitions
    • CONTRIBUTORS TO R&D SUCCESS
    • R&D SPENDING
      • Table Pharmaceutical/Biopharmaceutical R&D Statistics
      • Table Total Industry R&D Spending 2004-2010 ($Millions)
    • THE ROLE OF CONTRACT RESEARCH ORGANIZATIONS
    • SUSTAINABILITY IN A CHANGING PHARMACEUTICAL INDUSTRY
  • Worldwide Pharmaceutical Industry Leaders
    • INTRODUCTION
      • Table Top Biopharmaceutical Companies, 1-20 by 2011 Sales (millions)
    • PFIZER, INC.
      • Overview
      • Financial Performance and Investments
        • Table Pfizer's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Pfizer's Late Stage Product Pipeline
    • MERCK&CO., INC.
      • Overview
      • Financial Performance and Investments
        • Table Merck's* Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Merck's Late Stage Product Pipeline
    • NOVARTIS AG
      • Overview
      • Financial Performance and Investments
        • Table Novartis' Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Novartis' Late Stage Product Pipeline
    • SANOFI
      • Overview
      • Financial Performance and Investments
        • Table Sanofi's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Sanofi-Aventis' Late Stage Product Pipeline
    • ROCHE LTD.
      • Overview
      • Financial Performance and Investments
        • Table Roche's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Roche's Late Stage Product Pipeline
    • GLAXOSMITHKLINE PLC
      • Overview
      • Financial Performance and Investments
        • Table GlaxoSmithKline's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table GlaxoSmithKline's Late Stage Product Pipeline
    • ASTRAZENECA PLC
      • Overview
      • Financial Performance and Investments
        • Table AstraZeneca's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table AstraZeneca's Late Stage Product Pipeline
    • JOHNSON &JOHNSON
      • Overview
      • Financial Performance and Investments
        • Table Johnson & Johnson's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Johnson & Johnson's Late Stage Product Pipeline
    • ELI LILLY &COMPANY
      • Overview
      • Financial Performance and Investments
        • Table Eli Lilly's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Eli Lilly's Late Stage Product Pipeline
    • ABBOTT LABORATORIES
      • Overview
      • Financial Performance and Investments
        • Table Abbott's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Abbott's Late Stage Product Pipeline
    • BRISTOL-MYERS SQUIBB COMPANY
      • Overview
      • Financial Performance and Investments
        • Table Bristol-Myers Squibb's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Bristol-Myers Squibb's Late Stage Product Pipeline
    • TAKEDA PHARMACEUTICAL CO., LTD.
      • Overview
      • Financial Performance and Investments
        • Table Takeda's Total Company Revenue* and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Takeda Pharmaceutical's Late Stage Product Pipeline
    • TEVA PHARMACEUTICAL INDUSTRIES, LTD.
      • Overview
      • Financial Performance and Investments
        • Table TEVA's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table TEVA's Late Stage Product Pipeline
    • AMGEN, INC.
      • Overview
      • Financial Performance and Investments
        • Table Amgen's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Amgen's Late Stage Product Pipeline
    • BOEHRINGER INGELHEIM GMBH
      • Overview
      • Financial Performance and Investments
        • Table Boehringer Ingelheim's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Boehringer Ingelheim's Late Stage Product Pipeline
    • BAYER AG
      • Overview
      • Financial Performance and Investments
        • Table Bayer's Total Company Revenue and R&D Spending 2007-2011 (Millions)
      • Late Stage Pipeline
        • Table Bayer's Late Stage Product Pipeline
    • NOVO NORDISK
      • Overview
      • Financial Performance and Investments
        • Table Novo Nordisk's Total Company Revenue and R&D Spending 2007-2011 (millions)
      • Late Stage Pipeline
        • Table Novo Nordisk's Late Stage Product Pipeline
    • ASTELLAS
      • Overview
      • Financial Performance and Investments
        • Table Astellas' Total Company Revenue and R&D Spending 2007-2011 (millions)
      • Late Stage Pipeline
        • Table Astellas' Late Stage Product Pipeline
    • DAIICHI SANKYO
      • Overview
      • Financial Performance and Investments
        • Table Daiichi Sankyo's Total Company Revenue and R&D Spending 2007-2011 (millions)
      • Late Stage Pipeline
        • Table Daiichi Sankyo's Late Stage Product Pipeline
    • OTSUKA
      • Overview
      • Financial Performance and Investments
        • Table Otsuka Holding's Total Company Revenue and R&D Spending 2007-2011 (Thousands)
      • Late Stage Pipeline
        • Table Otsuka Pharmaceutical's Late Stage Product Pipeline
  • Companies of Interest
    • INTRODUCTION
      • Table Top Biopharmaceutical Companies, 21-50 by 2011 Sales (millions)
    • MERCK KGAA
      • Late Stage Pipeline
        • Table Merck KGaA's Late Stage Product Pipeline
    • GILEAD SCIENCES
      • Late Stage Pipeline
        • Table Gilead Sciences' Late Stage Product Pipeline
    • EISAI
      • Late Stage Pipeline
        • Table Eisai's Late Stage Product Pipeline
    • MYLAN
      • Pipeline
    • BAXTER INTERNATIONAL
      • Pipeline
    • SERVIER, LES LABORATORIES
      • Pipeline
    • CELGENE CORPORATION
      • Late Stage Pipeline
        • Table Celgene's Late Stage Product Pipeline
    • MITSUBISHI TANABE
      • Late Stage Pipeline
        • Table Mitsubishi Tanabe's Late Stage Product Pipeline
    • ALLERGAN
      • Late Stage Pipeline
        • Table Allergan's Late Stage Product Pipeline
    • FOREST LABORATORIES
      • Late Stage Pipeline
        • Table Forest Laboratories' Late Stage Product Pipeline
    • CSL LIMITED
      • Late Stage Pipeline
    • UCB SA
      • Late Stage Pipeline
        • Table UCB Pharma's Late Stage Product Pipeline
    • DAINIPPON SUMITOMO PHARMA, CO., LTD.
      • Late Stage Pipeline
        • Table Dainippon Sumitomo's Late Stage Product Pipeline
    • SHIRE
      • Late Stage Pipeline
        • Table Shire's Late Stage Product Pipeline
    • BIOGEN IDEC
      • Late Stage Pipeline
        • Table Biogen Idec's Late Stage Product Pipeline
    • WATSON
      • Pipeline
    • HOSPIRA
      • Late Stage Pipeline
        • Table Hospira's Late Stage Product Pipeline
    • LUNDBECK A/S
      • Late Stage Pipeline
        • Table Lundbeck's Late Stage Product Pipeline
    • KYOWA KIRIN
      • Late Stage Pipeline
        • Table Kyowa Kirin's Late Stage Product Pipeline
    • WARNER CHILCOTT PLC
      • Late Stage Pipeline
    • MENARINI GROUP
      • Late Stage Pipeline
        • Table Menarini's Late Stage Product Pipeline
    • VALEANT PHARMACEUTICALS
      • Late Stage Pipeline
        • Table Valeant's Late Stage Product Pipeline
    • PURDUE PHARMA
      • Late Stage Pipeline
    • GRIFOLS SA
      • Late Stage Pipeline
    • SHIONOGI &CO., LTD.
      • Late Stage Pipeline
        • Table Shionogi's Late Stage Product Pipeline
    • ACTELION
      • Late Stage Pipeline
        • Table Actelion's Late Stage Product Pipeline
    • ONO PHARMACEUTICAL CO.
      • Late Stage Pipeline
        • Table Ono Pharmaceutical's Late Stage Product Pipeline
    • SANTEN PHARMACEUTICAL CO.
      • Late Stage Pipeline
        • Table Santen's Late Stage Product Pipeline
    • RECKITT BENCKISER
      • Late Stage Pipeline
    • TAISHO PHARMACEUTICAL CO.
      • Late Stage Pipeline
        • Table Taisho's Late Stage Product Pipeline
  • Market Forecast
    • OVERVIEW
    • COMPANY ANALYSIS
      • Table Top Biopharmaceutical Companies, 1-50 by 2011 Sales (millions)
    • PIPELINE SNAPSHOT: TOP 20 COMPANIES
      • Table Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
    • MARKET TRENDS AND VALUE
      • Table Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010 ($ in billions)
    • EVALUATING CHANGES IN 2011 MARKET VALUE
      • Table Global Pharmaceutical Market Value by Therapeutic Segment, 2010 vs. 2011 ($ in billions)
    • MARKET FORECAST
      • Table Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016-based on late stage development projects evaluated ($ in billions)
    • THE TRADITIONAL BIOTECHNOLOGY MARKET
      • Table Top 5 Biotechnology Companies*, 2011 Sales (millions)
      • Biotechnology Market Facts and Forecast
        • Table Top 10 Biotechnology and Pharmaceutical Products, by 2011 Revenues (millions)
  • List of Companies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report